Compare CRL & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRL | SNN |
|---|---|---|
| Founded | 1947 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 12.3B |
| IPO Year | 1999 | 2002 |
| Metric | CRL | SNN |
|---|---|---|
| Price | $353.71 | $30.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 6 |
| Target Price | ★ $314.20 | $32.32 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 11-04-2026 | 08-04-2026 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,857,601,000.00 | N/A |
| Revenue This Year | N/A | $4.89 |
| Revenue Next Year | $2.53 | $5.25 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | ★ 10.48 | N/A |
| 52 Week Low | $146.20 | $26.30 |
| 52 Week High | $351.21 | $37.09 |
| Indicator | CRL | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 75.56 | 70.39 |
| Support Level | $147.39 | $29.18 |
| Resistance Level | N/A | $30.52 |
| Average True Range (ATR) | 12.96 | 0.46 |
| MACD | 4.91 | 0.39 |
| Stochastic Oscillator | 95.56 | 84.11 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.